Whalesbook
Aggressive Pricing to Boost Patient Access
Natco Pharma is entering the semaglutide market as the innovator product's patent expires. The company aims to significantly increase patient access by offering its generic version at a steep discount. The multi-dose vials, sold under the brands SEMANAT and SEMAFULL, are priced at just ₹1,290 per month. This makes the drug about 70% cheaper than existing pen devices and 90% less than the original branded medication.
CDSCO Approval and Future Pen Version
Natco Pharma's aggressive pricing is possible due to its efficient manufacturing and immediate market entry after the patent expired. The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and sell the product. Natco also plans to launch a pen device version in April 2026, expected to cost between ₹4,000 and ₹4,500 per month. This strategy aims to capture a wider range of patients.
Investor Reaction and Recent Activity
The market has responded positively to Natco Pharma's launch. The company's shares increased by 3.20% to ₹968.10. This jump shows investor confidence in Natco Pharma's product launches and its strategy of capitalizing on patent expirations. This semaglutide launch follows Natco's recent move in the United States, where it partnered with Breckenridge Pharmaceutical to launch a generic version of Celgene's Pomalyst.